Skip to main content

Table 3 Effect of baseline covariates on hepatotoxicity in cohort (including HIV infection and hematologic malignancy, n = 1,007)

From: Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study

Covariate *

Covariate present

Covariate absent

P value Ï®

 

Treatment episodes

Hepatotoxic episodes (%)

Treatment episodes

Hepatotoxic episodes (%)

 

Hepatitis C§

158

8(5.1)

849

26(3.1)

0.201

HIV infection§

25

4(16.0)

982

30(3.1)

0.008

Hematologic malignancy§

23

4(17.4)

984

30(3.1)

0.006

HBV antiviral prescription¶

29

5(17.2)

978

29(3.0)

0.002

Oral glucocorticoid prescription¶

364

19(5.2)

643

15(2.3)

0.015

Statin prescription¶

364

11(3.0)

643

23(3.6)

0.64

  1. *Defined within 12 months of index date unless otherwise specified; Ϯchi-square or Fisher’s exact test; §defined by International Classification of Diseases, Ninth Revision (ICD-9) codes 070.41, 070.44, 070.51, V0262 (hepatitis C), 042.XX (HIV infection), 200–208.92 (hematologic malignancy); ¶prescription within six months of index date. HIV, human immunodeficiency virus.